X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x - 32.9 - View Chart
P/BV x 5.9 3.0 198.4% View Chart
Dividend Yield % 0.7 0.6 128.9%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CIPLA
Mar-18
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,589663 239.7%   
Low Rs1,232479 257.2%   
Sales per share (Unadj.) Rs417.5189.0 220.8%  
Earnings per share (Unadj.) Rs56.317.6 320.0%  
Cash flow per share (Unadj.) Rs64.734.0 190.2%  
Dividends per share (Unadj.) Rs12.703.00 423.3%  
Dividend yield (eoy) %0.90.5 171.4%  
Book value per share (Unadj.) Rs292.9176.7 165.8%  
Shares outstanding (eoy) m119.57805.12 14.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 111.9%   
Avg P/E ratio x25.132.5 77.2%  
P/CF ratio (eoy) x21.816.8 129.9%  
Price / Book Value ratio x4.83.2 149.0%  
Dividend payout %22.617.1 132.3%   
Avg Mkt Cap Rs m168,653459,724 36.7%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m9,17126,901 34.1%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m49,915152,193 32.8%  
Other income Rs m1,6453,577 46.0%   
Total revenues Rs m51,561155,769 33.1%   
Gross profit Rs m8,48228,264 30.0%  
Depreciation Rs m1,00613,228 7.6%   
Interest Rs m6711,142 58.7%   
Profit before tax Rs m8,45117,470 48.4%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1,6062,501 64.2%   
Profit after tax Rs m6,73114,166 47.5%  
Gross profit margin %17.018.6 91.5%  
Effective tax rate %19.014.3 132.7%   
Net profit margin %13.59.3 144.9%  
BALANCE SHEET DATA
Current assets Rs m27,062108,141 25.0%   
Current liabilities Rs m15,32438,322 40.0%   
Net working cap to sales %23.545.9 51.3%  
Current ratio x1.82.8 62.6%  
Inventory Days Days6797 68.6%  
Debtors Days Days4174 55.5%  
Net fixed assets Rs m12,610109,411 11.5%   
Share capital Rs m2391,610 14.8%   
"Free" reserves Rs m34,490140,682 24.5%   
Net worth Rs m35,027142,292 24.6%   
Long term debt Rs m1,21236,621 3.3%   
Total assets Rs m54,387228,606 23.8%  
Interest coverage x13.616.3 83.5%   
Debt to equity ratio x00.3 13.4%  
Sales to assets ratio x0.90.7 137.9%   
Return on assets %13.66.7 203.2%  
Return on equity %19.210.0 193.0%  
Return on capital %24.910.0 249.7%  
Exports to sales %12.932.8 39.5%   
Imports to sales %3.10-   
Exports (fob) Rs m6,46149,883 13.0%   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56351,691 12.7%   
Fx outflow Rs m3,01221,033 14.3%   
Net fx Rs m3,55230,658 11.6%   
CASH FLOW
From Operations Rs m7,25914,628 49.6%  
From Investments Rs m1,864-8,540 -21.8%  
From Financial Activity Rs m-9,273-3,855 240.5%  
Net Cashflow Rs m-1502,431 -6.2%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 22, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS